[{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hypromellose","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Nasus Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nasus Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hypromellose","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Nasus Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nasus Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hypromellose","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nasus Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nasus Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hypromellose","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nasus Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nasus Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nasus Pharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Nasus Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : FMXIN002 (epinephrine) is an adrenergic receptor agonist small molecule drug candidate, which is currently being evaluated for the treatment of anaphylaxis via intranasal spray.

                          Brand Name : FMXIN002

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 05, 2023

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Taffix powder creates a unique thin acidified gel above the nasal mucosa that lasts 5 hours, significantly shielding the nasal cells from inhaled viruses through both mechanical and chemical protection.

                          Brand Name : TaffiX

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 16, 2021

                          Lead Product(s) : Hypromellose

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Taffix® powder creates a unique thin acidified gel above the nasal mucosa that lasts 5 hours, significantly shielding the nasal cells from inhaled viruses through both mechanical and chemical protection.

                          Brand Name : Taffix

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 16, 2021

                          Lead Product(s) : Hypromellose

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Data from a prospective clinical post marketing users survey shows that TaffixTM effectively blocks viruses from reaching nasal mucosa and was able to reduce infection rate of SARS-CoV-2 virus after super spread event by at least 4 fold.

                          Brand Name : TaffiX

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 13, 2020

                          Lead Product(s) : Hypromellose

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Gel layer produced by TaffiX® powder after administration of a clinical equivalent amount, effectively blocked SARS-CoV-2 virus, as demonstrated by four log reduction in amount of viral RNA and reduced the amount of infectious live virus by more than 99...

                          Brand Name : TaffiX

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 07, 2020

                          Lead Product(s) : Hypromellose

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank